Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections - A Look At Taiwan (Part 2)
This article was originally published in PharmAsia News
Executive Summary
Asian drug regulatory authorities are subjecting applicants to increasingly extensive chemistry, manufacturing and controls reviews, more like those of first-tier authorities in the U.S. and Europe